Howard Marks
Oaktree Capital Management
Howard Marks Sorrento Therape stake
total: 853
Oaktree Capital Management SRNE trades
- Total transactions:
- 7
- New positions:
- 2
- Sold out:
- 2
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2021 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2023 Q2
According to 2026 Q2 report, Howard Marks doesn't hold any Sorrento Therape (SRNE) shares. To date, the estimated cost basis is nearly $8.1 for "buy" trades and estimated average "sell" price is $5.6. Oaktree Capital Management first purchased SRNE in 2020 Q2, initially acquiring 100,500 shares. Howard Marks later completely sold out the position and invested in Sorrento Therape again in 2021 Q1. Since the initial investment in Sorrento Therape (SRNE), Oaktree Capital Management has made 6 more transactions.
When did Howard Marks sell Sorrento Therape (SRNE)?
Howard Marks sold off the entire Sorrento Therape (SRNE) position in 2023 Q2.
When did Howard Marks buy Sorrento Therape (SRNE)?
Howard Marks first invested in Sorrento Therape (SRNE) in 2020 Q2 at the reported quarter-end price of $6.28 per share.
What's the cost basis of Oaktree Capital Management's SRNE stake?
The estimated cost basis for Sorrento Therape (SRNE) stake is around $8.10 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $8.10
- Weighted AVG sell price:
- $5.60
Howard Marks's historical trades in Sorrento Therape
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$0.36
|
|
-100% (-134,000)
|
-0%
|
|
2022 Q2
|
0.00%
|
134,000
|
$2.01
|
$269,000
|
-10.67% (-16,000)
|
-0%
|
|
2021 Q4
|
0.01%
|
150,000
|
$4.65
|
$697,000
|
+11.94% (+16,000)
|
+0%
|
|
2021 Q2
|
0.02%
|
134,000
|
$9.68
|
$1,297,000
|
-58.12% (-186,000)
|
-0.03%
|
|
2021 Q1
|
0.04%
|
320,000
|
$8.27
|
$2,646,000
|
new
|
+0.04%
|
|
2020 Q3
|
0.00%
|
$6.28
|
-100% (-100,500)
|
|||
|
2020 Q2
|
0.01%
|
$6.28
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.